In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.

Center for Biostatistics in AIDS Research, Harvard School of Public Health , Boston, MA, USA.
AIDS patient care and STDs (Impact Factor: 2.68). 07/2011; 25(7):385-94. DOI: 10.1089/apc.2011.0068
Source: PubMed

ABSTRACT An increasing number of antiretroviral agents (ARVs) are approved for use, but their use during pregnancy in the United States has not been completely described. We used data from the Pediatric HIV/AIDS Cohort Study (PHACS) Surveillance Monitoring for ART Toxicities (SMARTT) study, a United States-based prospective cohort study of HIV-exposed but uninfected children, to assess temporal trends and maternal characteristics associated with the use of ARVs during pregnancy. The proportion of children exposed in utero to ARVs was calculated over time. A multivariable logistic regression model was used to estimate associations of maternal characteristics with use of highly active antiretroviral therapy (HAART) during pregnancy. We studied 1768 HIV-exposed but uninfected children born between 1995 and 2009 and enrolled in SMARTT. Prenatal HAART exposure increased from 19% in 1997 to 88% in 2009. Of children born in 2009, 99% had prenatal exposure to NRTIs (including zidovudine, 73%; lamivudine, 72%; tenofovir, 39%; and emtricitabine, 37%). Exposure to protease inhibitors increased from 15% in 1997 to 86% in 2009, while exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs) declined from 33% in 2003 to 11% in 2009. Higher maternal HIV RNA viral load (VL) concentration, lower maternal CD4 count, and earlier timing of the first maternal CD4 or VL measurement during pregnancy were associated with increased odds of HAART exposure. Prenatal HAART exposure has increased but is not universal. As ARV use during pregnancy continues to evolve, follow-up of children is needed to assess long-term effects of ARV exposures.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tenofovir (TFV) is used in pregnant women as a part of combination antiretroviral treatment to prevent mother-to-child transmission of HIV infection. We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2). We employed in-vitro cell-based assays and in-situ animal model to assess possible role of the efflux transporters in transplacental pharmacokinetics of TFV and TDF. In-vitro transport assays were performed in MDCKII cells transduced with human ABCB1, ABCG2 or ABCC2. To quantify the effect of these transporters on TFV/TDF transplacental passage, we employed the in-situ model of dually perfused rat term placenta in open and closed setup. In-vitro assays revealed that TDF is a dual substrate of ABCB1 and ABCG2 but not of ABCC2. In contrast, TFV transport was not influenced by any of these transporters. Applying concentration-dependent studies and selective inhibitors, we further confirmed these findings in situ on the organ level; both ABCB1 and ABCG2 limited mother-to-fetus transfer of TDF whereas TFV transplacental passage was not affected by these ABC transporters. We propose limited mother-to-fetus transport of both TFV and TDF. While placental transport of TFV is restricted passively, by physical-chemical properties of the molecule, mother-to-fetus passage of TDF is actively hindered by placental ABCB1 and ABCG2 transporters, pumping this compound from trophoblast back to maternal circulation.
    AIDS 01/2014; 28(1):9-17. · 6.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Optimal use of antiretroviral drugs by pregnant women living with human immunodeficiency virus (HIV) is crucial to treat maternal HIV infection and prevent perinatal transmission of the virus effectively. Our goal was to describe national trends of antiretroviral (ARV) use during pregnancy among HIV-infected women living in the U.S. and enrolled in Medicaid. We used the 2000-2007 Medicaid Analytic eXtract (MAX) files to identify our study cohort. ARV use was defined as the dispensing of at least one ARV drug prescription during pregnancy based on Medicaid pharmacy claims. The prevalence of HIV was calculated, and temporal trends of ARV use during pregnancy were compared to the U.S. perinatal treatment guidelines. Predictors of ARV use during pregnancy were assessed using logistic regression models. From 1,106,757 pregnancies (955,251 women), 3083 (2856 women, 0.28%) were identified as HIV positive. We found striking regional variations in the prevalence of HIV and ARV prescription dispensing among pregnant women. The states with the highest HIV prevalence were Washington DC (5.8%), Maryland (0.90%), and New York (0.89%); all other states had a prevalence below 0.5%. A substantial fraction of women did not have any ARV dispensing throughout pregnancy (637 of 3083 (21%) pregnancies), and women with limited health care utilization were the least likely to have ARV dispensings. This finding calls for further research to better characterize HIV-positive women who are enrolled in Medicaid prior to pregnancy and yet have no ARV prescriptions so that appropriate interventions can be implemented.
    AIDS patient care and STDs 02/2014; 28(2):56-65. · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Long-term effects of in utero and neonatal antiretroviral (ARV) exposure on cognitive and academic development in HIV-exposed, uninfected school-age children are unknown.
    The Pediatric Infectious Disease Journal 11/2014; 33(11):1128-33. · 3.14 Impact Factor

Full-text (2 Sources)

Available from
Jun 10, 2014